# A Study in Schizophrenia Patients

> **NCT01086748** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 880 (estimated)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Risperidone
- **DRUG:** Placebo
- **DRUG:** LY2140023

## Key facts

- **NCT ID:** NCT01086748
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2012-05
- **Final completion:** 2012-05
- **Target enrollment:** 880 (ESTIMATED)
- **Last updated:** 2012-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01086748

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01086748, "A Study in Schizophrenia Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01086748. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*